Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies

Diagnostic Cytopathology

Volumn 37, Issue 9, 2009, Pages 629-635

  Nassar, Aziza ^a   Cohen, C ^b   Siddiqui, M T ^b  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell blocks; Glypican 3; Hepatocellular carcinoma; Survivin

Indexed keywords

GLYPICAN 3; HEPATOCYTE PARAFFIN 1 PROTEIN; SURVIVIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION BIOPSY; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER NODULE; MAJOR CLINICAL STUDY; NODULAR HYPERPLASIA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; PRECANCEROUS CONDITIONS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 68849113736     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21075     Document Type: Article

References (36)

1. Filmus J, Capurro M. Glypican-3 and alpha-fetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004;8:207-212. (Pubitemid 40994223)
2. Hippo Y, Watanabe K, Watanabe A, et al. Identification of a soluble NH2-terminal fragment of glypican-3 as a serologic marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-2423. (Pubitemid 38523895)
3. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. (Pubitemid 36799110)
4. Zynger DL, Dimov ND, Luan C, Teh BT, Yang XJ. Glypican-3: A novel marker in testicular germ cell tumors. Am J Surg Pathol 2006; 30:1570-1575. (Pubitemid 44808793)
5. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598. (Pubitemid 41670658)
6. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis. dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30:405-1411. (Pubitemid 44655475)
7. Wang XY, Degos F, Dubois S, et al. Glypican-3 Expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441. (Pubitemid 44739946)
8. Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, et al. Distinction of Hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and cd34 immunohistochemistry. Am J Surg Pathol 2008;32:433-444.
9. Chau G-Y, Lee A F-Y, Tsay S-H, et al. Clinic pathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 2007;51:204-218. (Pubitemid 47083982)
10. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in hcv cirrhosis. Gastroenterology 2006;131:1758-1767. (Pubitemid 46001394)
11. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: Correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 2004;17:1378-1385. (Pubitemid 39472993)
12. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003;3:46-54. (Pubitemid 37328886)
13. Siddiqui MT, Saborrian MH, Gokaslan ST, Ashfaq R. Diagnostic utility of the hepar-1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine- needle aspiration samples. Cancer 2001;96:49-52. (Pubitemid 34194320)
14. Onofre AS, Pomjanski N, Buckstegge B, Böcking A. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies. Cancer 2007;111:259-268. (Pubitemid 47301285)
15. Wang L, Vuolo M, Suhrland MJ, Schlesinger K. HepPar1. MOC31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs metastatic adenocarcinoma in liver fine needle apirates. Acta Cytol 2006;50:257-262. (Pubitemid 43837037)
16. Wennerberg A, Ma N, Coleman W. Hepatocyte Paraffin 1: A monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol 1993;143:1050-1054. (Pubitemid 24070547)
17. Jakubovic BD, Jothy S. Glypican-3: From the mutations of simpson-golabi-behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol 2007;82:184-189. (Pubitemid 46486730)
18. Zu ZW, Friess H, Wang L, Abou-Shady M, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564. (Pubitemid 32234802)
19. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biologic significance and temporospatial distribution. Cancer Res 1997;57:5179-5184. (Pubitemid 27498138)
20. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirate: A novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer 2007;111:316-322.
21. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas from Cirrhosis. Dysplastic Nodules, and Focal Nodular Hyperplasia-like Nodules. Am J Surg Pathol 2006;30:1405-1411. (Pubitemid 44655475)
22. Varma V, Cohen C. Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma. Adv Anat Pathol 2004;11:239-249.
23. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 2005;19:71-77. (Pubitemid 40559473)
24. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, over-expressed in hepatocellular carcinoma, modulates fgf2 and bmp-7 signaling. Int J Cancer 2003;103:455-465. (Pubitemid 36020219)
25. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008;21:1011-1018.
26. Anatelli F, Chuang ST, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol 2008;130:219-223.
27. Ligato S, Mandich D, Cartum RW. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: An immunocytochemical study. Mod Pathol 2008;21:626-631. (Pubitemid 351589657)
28. Hishinuma M, Ohashi KI, Yamauchi N, et al. Hepatocellular oncofetal protein, glypican 3 is a sensitive marker for α-fetoprotein-producing gastric carcinoma. Histopathology 2006;49:479-486. (Pubitemid 44631620)
29. Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L, Singer G. Glypican-3 expression in primary and recurrent ovarian carcinomas. Int J Gynecol Pathol 2007;26:341-344. (Pubitemid 46986073)
30. Zynger D, Everton MJ, Dimov ND, Chou PM, Yang XJ. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol 2008;130:224-230.
31. Nassar A, Lawson D, Cotsonis G, Cohen C. Survivin and caspase-3 expression in breast cancer: Correlation with prognostic parameters, proliferation, angiogenesis and outcome. Appl Immunohistochem Mol Morphol 2008;16:113-120.
32. Nassar A, Sexton D, Cotsonis G, Cohen C. Survivin expression in breast carcinoma: Correlation with apoptosis and prognosis. Appl Immunohistochem Mol Morphol 2008;16:221-226. (Pubitemid 351589545)
33. Lugli A, Tornillo L, Mirlacher M, Bundi M, Sauter G, Terracciano LM. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues. Am J Clin Pathol 2004;122:721-727.
34. Chu PG, Ishizawa S, Wu W, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: An immunohistochemical comparison to carcinoembryonic antigen CD10 and Alpha-fetoprotein. Am J Surg Pathol. 2002;26:978-988. (Pubitemid 34810558)
35. Lee HS, Kim WH, Kang GH. Hepatocyte expressions in hepatocellular carcinomas, gastrointestinal neoplasms, and non-neoplastic gastrointestinal mucosa: Its role as a diagnostic marker. J Korean Med Sci 2003;18:642-848.
36. Wieczorek TJ, Pinkus JL, Glickman JN, Pinkus GS. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma. metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol 2002;118:911-921.